RxDoctor Payments Data

Russell Stapleton, MD

Nuclear Cardiology · Fernandina Beach, FLNPI 1265498976

Payments from drug & device makers

$197,461in general payments, 2019–2025

Across 396 payments — averaging $498.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$190K
  • Abbott$918
  • Novartis$808
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$677
  • Pfizer$671
  • Merck$540
  • plus $4K from 34 others

What the payments were for

  • Grants$160%
  • Food & beverage$8,702100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear cardiology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$330,067
Medicare patients
1,220
Services billed
4,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$343,110
EntrestoSacubitril/Valsartan95$120,524
FarxigaDapagliflozin Propanediol70$62,465
Repatha SureclickEvolocumab70$59,921
MultaqDronedarone Hcl28$47,236
XareltoRivaroxaban23$25,311
Repatha PushtronexEvolocumab28$21,502
JardianceEmpagliflozin15$16,897
Praluent PenAlirocumab35$16,816
Ezetimibe846$16,631
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide484$13,994
Metoprolol Succinate600$7,943
Atorvastatin Calcium695$7,381
Clonidine12$5,346
Nifedipine ErNifedipine138$3,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$671$343,110240 claims
NovartisEntresto$808$120,52495 claims
AstraZenecaFarxiga$342$62,46570 claims
Sanofi-aventis U.S. LLCMultaq$70$47,23628 claims
Johnson & JohnsonXarelto$211$25,31123 claims
Boehringer IngelheimJardiance$343$16,89715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Fernandina Beach

Where these figures come from

Is this you, or does something look wrong? →